nivolumab

Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is a leading cause of death among cancer patients. The 5-year overall survival rate in patients with localized cancer is 55.2 %, and this decreases to 4.3 % […]

Immune Checkpoint Inhibitors in Older Adults

Immune Checkpoint Inhibitors in Older Adults

Cancer is primarily a disease of the older adult with more than 50 % of new cases occurring in adults older than 65 years. The care of older adults with cancer can […]

Immune checkpoint inhibitors: a new frontier in bladder cancer

Immune checkpoint inhibitors: a new frontier in bladder cancer

  Immunotherapy and immune checkpoint inhibition in particular present an exciting opportunity for the treatment of bladder cancer. Over the last 30 years, bladder cancer patients have seen few advances in the […]

New Drug for Lung Cancer can Improve the Survival Rate Greatly

New Drug for Lung Cancer can Improve the Survival Rate Greatly

Scientists have found a drug called nivolumab more effective for non-small cell lung cancer, as it increases the survival time while bring less side effects than the traditional drug used […]